Company Encyclopedia
View More
name
Amarin
AMRN.US
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd.
1.946 T
AMRN.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking236/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-17.41%E
    • Profit Margin-38.01%E
    • Gross Margin44.71%B
  • Growth ScoreD
    • Revenue YoY-5.93%D
    • Net Profit YoY-119.06%E
    • Total Assets YoY-12.10%E
    • Net Assets YoY-13.64%E
  • Cash ScoreD
    • Cash Flow Margin-263.06%D
    • OCF YoY-5.93%D
  • Operating ScoreD
    • Turnover0.32D
  • Debt ScoreB
    • Gearing Ratio30.45%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Amarin (NASDAQ:AMRN) Stock Price Crosses Above 200 Day Moving Average - Should You Sell?

    Amarin Corporation's stock price crossed above its 200-day moving average, trading as high as $16.71. Analysts have mixed ratings: Wall Street Zen upgraded to "strong-buy," Weiss Ratings reiterated "sell," and Zacks Research downgraded to "hold." The stock has a market cap of $340.59 million and a negative P/E ratio. Institutional investors have adjusted their stakes, with 22.25% owned by hedge funds. Amarin offers VASCEPA for cardiovascular treatment. Despite the stock's "sell" rating, analysts suggest other stocks as better investments.

    Market Beat·
    US
    AMRN
    +1.04%
    Market Beat·
    US
    AMRN
    +1.04%

    New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients | AMRN Stock News

    Amarin Corporation presented a new analysis at the AHA Scientific Sessions 2025, reinforcing that icosapent ethyl (VASCEPA/VAZKEPA) significantly reduces cardiovascular events in high-risk patients. The analysis, based on the REDUCE-IT study, showed that icosapent ethyl reduced major adverse cardiovascular events by 28% in aspirin users. This comes after the FDA updated labeling for fibrates, indicating no cardiovascular benefit when used with statins. The findings emphasize the importance of effective therapies for managing cardiovascular risk.

    StockTitan·
    US
    AMRN
    +1.04%
    StockTitan·
    US
    AMRN
    +1.04%

    Amarin Unveils New REDUCE-IT Analyses Highlighting VASCEPA Efficacy at AHA 2025

    Amarin Corporation plc will present new analyses from the REDUCE-IT study at the American Heart Association’s Scientific Sessions 2025, focusing on the efficacy of Icosapent Ethyl (VASCEPA®/VAZKEPA®) for cardiovascular risk reduction. The presentations will include data on outcomes related to baseline aspirin use and mechanistic studies on the properties of Eicosapentaenoic Acid (EPA). Results will be shared during abstract and poster sessions at the conference, scheduled for November 7-10 in New Orleans, Louisiana.

    Reuters·
    US
    AMRN
    +1.04%
    Reuters·
    US
    AMRN
    +1.04%

    Amarin Corporation plc Files Initial Statement of Beneficial Ownership for EVP and Chief Operating Officer David Paul Keenan

    Amarin Corporation plc has filed an initial statement of beneficial ownership (Form 3) with the U.S. Securities and Exchange Commission, identifying David Paul Keenan as the beneficial owner. He serves as Executive Vice President and Chief Operating Officer of the company. The full filing is accessible through the SEC's EDGAR system.

    Reuters·
    US
    AMRN
    +1.04%
    Reuters·
    US
    AMRN
    +1.04%

    Amarin Corporation’s Earnings Call Highlights Growth and Challenges

    Amarin Corporation's earnings call highlighted a cautious optimism with a 17% increase in total net revenue to $49.7 million, driven by a 34% rise in U.S. net product revenue. The company successfully partnered with Recordati for European markets, achieving significant cost savings. However, challenges persist with declining Rest of World revenues and ongoing restructuring costs of $9.4 million, leading to an operating loss of $11.1 million. Looking ahead, Amarin aims for positive cash flow by 2026, focusing on expanding VASCEPA's market reach and benefiting from recent FDA labeling updates.

    Tip Ranks·
    US
    AMRN
    +1.04%
    Tip Ranks·
    US
    AMRN
    +1.04%
    © 2025 Longbridge｜Disclaimer